Skip to main content

Table 2 Results of pre-screening of patients eligible for the clinical trials GETUG 14, GETUG 15, GETUG 16, and GETUG 17

From: Improving the pre-screening of eligible patients in order to increase enrollment in cancer clinical trials

 

GETUG 14

GETUG 15

GETUG 16

GETUG 17

Total*

MDC team’s decisions (1)

17 (5.9%)

0

7 (2.4%)

2 (0.7%)

26 (9.1%)

CRA’s decisions (2)

59 (20.6%)

8 (2.8%)

13 (4.5%)

3 (1.0%)

83 (29.0%)

PI’s decisions (3)

30 (10.5%)

0

6 (2.1%)

1 (0.3%)

37 (12.9%)

  1. *McNemar’s chi-squared test: (1) versus (2) P <10−3; (1) versus (3) P = 0.022; (2) versus (3) P <10−3.
  2. (1) Decisions of the physicians during the multidisciplinary cancer (MDC) meetings; (2) Decisions of a clinical research assistant (CRA) after the systematic review of the MDC reports; (3) Final decisions after the principal investigator (PI) corrected the discrepancies between the MDC team’s and the CRA’s decisions.